Clonazepam: Sleep laboratory study of efficacy and withdrawal

Anthony Kales, Rocco L. Manfredi, Alexandros N. Vgontzas, Claudia F. Baldassano, Katherine Kostakos, Joyce D. Kales

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Clonazepam 0.5 mg was evaluated in a sleep laboratory study of 6 insomniac patients. The 16-night protocol consisted of 4 placebo-baseline nights, 7 nights of drug administration and 5 placebo-with-drawal nights. Clonazepam produced a significant decrease in total wake time initially (nights 5–7), as well as with continued administration (nights 9–11). With later but not immediate withdrawal, significant rebound insomnia occurred, on the 3rd withdrawal night, both wake time after sleep onset and total wake time increased markedly, with the latter significantly increased. These findings are discussed in light of clonazepam’s increasing use for panic disorder; specifically, due to its maintained efficacy, it has the advantage of avoiding interdose rebound anxiety which is frequently reported with use of alprazolam.

Original languageEnglish (US)
Pages (from-to)189-193
Number of pages5
JournalJournal of Clinical Psychopharmacology
Issue number3
StatePublished - Jun 1991

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Clonazepam: Sleep laboratory study of efficacy and withdrawal'. Together they form a unique fingerprint.

Cite this